Abcellera Biologics Inc (ABCL)

$11.20 -0.18 (-1.58%)
Market Cap 3.49B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 7,842,800
Avg Vol 7,983,604
Day's Range N/A - N/A
Shares Out 306.61M
Stochastic %K 93%
Beta 1.20
Analysts Strong Sell
Price Target $16.12

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
lustiger
lustiger Aug. 18 at 8:08 AM
$ABCL time table for phase 3, at least they can announce a planned start date
0 · Reply
PeelonDusk
PeelonDusk Aug. 18 at 6:13 AM
$ABCL Next catalyst?
0 · Reply
MacroSummit
MacroSummit Aug. 18 at 6:08 AM
$SOXS $BBAI $CBRS $ABCL SOXS provides leveraged inverse semiconductor exposure, BigBear.ai remains focused on AI analytics and defense opportunities, CBRS remains speculative, and AbCellera advances antibody-discovery partnerships. I'm watching semiconductor momentum, government contracts, funding, and biotech partnerships.
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 18 at 3:48 AM
$ABCL SETTING UP FOR A MAJOR SHORT SQUEEZE!!!! 👀
0 · Reply
SnoddyTradz
SnoddyTradz Aug. 18 at 3:46 AM
$BMNR $MLEC $ABCL Check out $IPST 400k float bout to pull a $VEEE 2.0🤑
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 18 at 3:30 AM
$ABCL $ABCL is quietly becoming the $PLTR of antibodies. Palantir built the data engine. ABCL is building the AI engine for drug discovery. They’re not just chasing one drug at a time. They’re creating the operating system that helps pharma companies find treatments faster. Their tech basically maps the immune system, sifting through millions of cells to hunt down the right antibody. Both companies are good at turning messy, massive datasets into something useful when everyone else just sees noise. $ABCL is trying to change how medicine gets made.
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 18 at 3:14 AM
$ABCL
0 · Reply
Bullock3000
Bullock3000 Aug. 18 at 2:15 AM
$ABCL Woot !! $10 handle
0 · Reply
Lolichocho
Lolichocho Aug. 18 at 1:42 AM
$ABCL 💰 💰 long from $2's, not selling anywhere near this low
0 · Reply
SammyStocks22
SammyStocks22 Aug. 18 at 12:46 AM
$ABCL wtf? We are trending #2 right now? Sure why not and heck yeah!
2 · Reply
Latest News on ABCL
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

Aug 13, 2026, 12:05 AM EDT - 5 days ago

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

AbCellera announces $200M common stock, warrants offering

2026-08-11T20:05:47.000Z - 6 days ago

AbCellera announces $200M common stock, warrants offering

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aug 11, 2026, 4:01 PM EDT - 6 days ago

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera price target raised to $30 from $12 at Truist

2026-08-11T13:35:37.000Z - 6 days ago

AbCellera price target raised to $30 from $12 at Truist

AbCellera price target raised to $25 from $13 at JonesResearch

2026-08-10T19:55:32.000Z - 7 days ago

AbCellera price target raised to $25 from $13 at JonesResearch

AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 8:00 AM EDT - 7 days ago

AbCellera Biologics Slides: Corporate presentation

AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 7 days ago

AbCellera Biologics Transcript: Study result

AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 7 days ago

AbCellera Biologics Press release: Study result

AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:30 AM EDT - 7 days ago

AbCellera Biologics Slides: Study result

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

Aug 10, 2026, 7:23 AM EDT - 7 days ago

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

Aug 10, 2026, 7:13 AM EDT - 7 days ago

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

2026-08-10T11:11:27.000Z - 7 days ago

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Aug 10, 2026, 7:00 AM EDT - 7 days ago

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Aug 7, 2026, 4:30 PM EDT - 10 days ago

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:20:50.000Z - 11 days ago

AbCellera price target raised to $9 from $8 at Stifel

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

2026-08-06T12:12:02.000Z - 11 days ago

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 12 days ago

AbCellera Biologics Earnings Call Transcript: Q2 2026

AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 12 days ago

AbCellera Biologics Slides: Q2 2026

AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 12 days ago

AbCellera Biologics Earnings release: Q2 2026

AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 12 days ago

AbCellera Biologics Quarterly report: Q2 2026

AbCellera Reports Q2 2026 Business Results

Aug 5, 2026, 4:05 PM EDT - 12 days ago

AbCellera Reports Q2 2026 Business Results

AbCellera announces collaboration with Vertex Pharmaceuticals

2026-07-29T11:27:06.000Z - 19 days ago

AbCellera announces collaboration with Vertex Pharmaceuticals

VRTX

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

Jul 29, 2026, 7:00 AM EDT - 19 days ago

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

2026-07-09T21:29:02.000Z - 5 weeks ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

Jul 7, 2026, 4:05 PM EDT - 5 weeks ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 5 weeks ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 6 weeks ago

AbCellera apponts Lynn Seely to board of directors

LYEL

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 6 weeks ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Jun 17, 2026, 7:43 AM EDT - 2 months ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jun 17, 2026, 7:00 AM EDT - 2 months ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 2 months ago

AbCellera appoints Victor Sandor to board of directors

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:40 AM EDT - 2 months ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 3 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings release: Q1 2026

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Quarterly report: Q1 2026

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Slides: Q1 2026

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 11, 2026, 4:05 PM EDT - 3 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 7, 2026, 4:05 PM EDT - 3 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera Biologics Slides: Corporate presentation

May 1, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Slides: Corporate presentation

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 21, 2026, 1:30 PM EDT - 4 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 20, 2026, 9:00 AM EDT - 4 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 1, 2026, 4:05 PM EDT - 4 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 17, 2026, 4:30 PM EDT - 5 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 5 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025

AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Feb 11, 2026, 4:05 PM EST - 6 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 7 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 7 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 7 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 8 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 9 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 10 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Quarterly report: Q3 2025

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings release: Q3 2025

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Slides: Q3 2025

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 1 year ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 1 year ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 2 years ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

lustiger
lustiger Aug. 18 at 8:08 AM
$ABCL time table for phase 3, at least they can announce a planned start date
0 · Reply
PeelonDusk
PeelonDusk Aug. 18 at 6:13 AM
$ABCL Next catalyst?
0 · Reply
MacroSummit
MacroSummit Aug. 18 at 6:08 AM
$SOXS $BBAI $CBRS $ABCL SOXS provides leveraged inverse semiconductor exposure, BigBear.ai remains focused on AI analytics and defense opportunities, CBRS remains speculative, and AbCellera advances antibody-discovery partnerships. I'm watching semiconductor momentum, government contracts, funding, and biotech partnerships.
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 18 at 3:48 AM
$ABCL SETTING UP FOR A MAJOR SHORT SQUEEZE!!!! 👀
0 · Reply
SnoddyTradz
SnoddyTradz Aug. 18 at 3:46 AM
$BMNR $MLEC $ABCL Check out $IPST 400k float bout to pull a $VEEE 2.0🤑
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 18 at 3:30 AM
$ABCL $ABCL is quietly becoming the $PLTR of antibodies. Palantir built the data engine. ABCL is building the AI engine for drug discovery. They’re not just chasing one drug at a time. They’re creating the operating system that helps pharma companies find treatments faster. Their tech basically maps the immune system, sifting through millions of cells to hunt down the right antibody. Both companies are good at turning messy, massive datasets into something useful when everyone else just sees noise. $ABCL is trying to change how medicine gets made.
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 18 at 3:14 AM
$ABCL
0 · Reply
Bullock3000
Bullock3000 Aug. 18 at 2:15 AM
$ABCL Woot !! $10 handle
0 · Reply
Lolichocho
Lolichocho Aug. 18 at 1:42 AM
$ABCL 💰 💰 long from $2's, not selling anywhere near this low
0 · Reply
SammyStocks22
SammyStocks22 Aug. 18 at 12:46 AM
$ABCL wtf? We are trending #2 right now? Sure why not and heck yeah!
2 · Reply
SammyStocks22
SammyStocks22 Aug. 18 at 12:45 AM
$ABCL I don’t like making timeline calls because it makes you wrong most of the time. I think this can be $20 plus easy in a month to a few months time.
0 · Reply
SammyStocks22
SammyStocks22 Aug. 18 at 12:40 AM
$ABCL charts are cool and all. But when you start talking about pullbacks and RSI needs to cool down. It doesn’t always apply. This does deserve more and imo it’ll get more. Maybe if this ran to $24 plus it might need to cool down but also wouldn’t be surprised if it leaves that in the dust as well.
1 · Reply
Merlintrader
Merlintrader Aug. 18 at 12:29 AM
$ABCL AbCellera Biologics Stock Hub 2026: ABCL635 Phase 2 data, Q2 liquidity and the priced US$200 million offering https://www.merlintrader.com/abcellera-biologics-stock-hub/
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 18 at 12:22 AM
$ABCL potential to cause shorts a LOT of pain…. Judging a stock "expensive" because it's high from its 52-week low, regardless of whether the low was ever justified. Inverse is also true. $ABCL The dam is about to break….
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 18 at 12:12 AM
$ABCL $ABCL BULLISH HITS DETECTED
0 · Reply
JiZzM0pper216
JiZzM0pper216 Aug. 18 at 12:08 AM
$ABCL 2 monumental stories What to expect? $RGNX? Lol
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 18 at 12:05 AM
$ABCL Much higher prices coming by the end of this week $13-$15 ☝️👀👀 Just reread Carl Hansens letter to shareholders in the 2025 $ABCL annual report and it reminded me of Bezos’ 2000 letter after AMZN went down 80% while all of the fundamentals improved considerably. Same vibes. Also, bezos famously mentions a story of how he was second best in his physics class, and knew he wasn’t good enough to be a physicist. Carl says same thing in his UT speech to students…interesting data points.
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 18 at 12:04 AM
$ABCL $ABCL RELENTLESS 👀
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 18 at 12:01 AM
$ABCL $ABCL if you are Canadian 🇨🇦, you must seriously consider owning AbCellera. This company is a future pillar of your country. AbCellera will be bigger than Hockey. Bigger than maple syrup. More famous than Tim Hortons. Tag the best Canadian investors you know in the comments.
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 17 at 11:54 PM
$ABCL $ABCL Management really was thinking ahead. The IP protections AbCellera gains from their new facility can also extend to their partners. No need for a third party manufacturer, big value prop and differentiator for partnerships just as the AI-drug discovery race is heating up 🤝
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 17 at 11:52 PM
$ABCL $ABCL institutional continued loading snapshot. This all didn’t happen on Friday, but shows accumulation leading into phase 2 data. We are just getting started!
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 17 at 11:51 PM
$ABCL Feels good when a biostatistician that designs RCTs for a living is a fellow long investor in $ABCL, and shares their analysis of phase 2 data. TLDR: The data is some of the best they’ve ever seen and the path ahead looks like clear skies and rainbows barring any safety signals in larger trials.
0 · Reply